Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness
More News related to BMRN
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
- Morgan Joseph Reiterates a 'Buy' on BioMarin Pharmaceutical (BMRN)
- Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
- BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
More News related to GENZ
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
- PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
More News related to Analyst Comments
- Verizon (VZ) Executive McAdam Buys 17K Shares
- Herbalife (HLF) CEO Enters Trading Plan Covering 732K Shares
Baird said they are buyers of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) on weakness tied to Genzyme Corp. (Nasdaq: GENZ) Allston manufacturing suspension.
The firm notes, "Aldurazyme fill/finish was previously performed at this facility, but BMRN indicates Allston is now a secondary source and an outside, primary source has been validated for some time. Coupling this with BMRN's indication that at least a year's worth of Aldurazyme finished goods inventory is on hand, we see no impact to BMRN's revenue prospects."
Related Categories
Analyst CommentsStocks Mentioned
-0.03
+0.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
